Zacks Analyst Blog Highlights: CDC Corp., Isis Pharmaceuticals, Inc., Genzyme Corp., Priceline.Com and American Oil & Gas, Inc.

Isis Reports Financial Results and Highlights for Third Quarter of 2008

Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis

Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review

Webcast Alert: Isis Pharmaceuticals Announces Third Quarter 2008 Financial Results Conference Call

Isis' Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting

Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics

Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., Schering- Plough Corp., Sara Lee Corp., EnCana Corp. And Euroseas Ltd.

Webcast Alert: ATL/TV1102 Phase II Results Presented at the World Congress on Treatment and Research in Multiple Sclerosis Conference Call

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents

Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors

Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors

Isis Initiates Clinical Trial of CRP Drug

Isis Reports Financial Results and Highlights for Second Quarter of 2008

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance

Webcast Alert: Isis Pharmaceuticals Announces Second Quarter 2008 Financial Results Conference Call

Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer

Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call

Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences

Isis Pharmaceuticals Conference Call Notice

Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies

Genzyme and Isis Complete Licensing of Mipomersen

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference

Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update in Conjunction With 2008 Annual Meeting of Stockholders

Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology

Isis to Receive $4.6 Million From Alnylam

Isis Files S-3 Registration Statement

Isis Reports Financial Results and Highlights for First Quarter of 2008

New Analyst Reports for GILEAD SCIENCES INC, ISIS PHARMACEUTICALS INC, CURIS INC, and MILLENNIUM PHARMACEUTICALS INC

Webcast Alert: Isis Pharmaceuticals Announces First Quarter 2008 Financial Results Conference Call

Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases

FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance

GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE